Compare Stocks: ATXS, DYN, ELVN, and RCUS

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ATXS Astria Therapeutics	$12.58 +0.6%	$12.68	$3.69 ▼ $13.29	$718.13M	0.01	1.01 million shs	3.20 million shs
DYN Dyne Therapeutics	$15.62 -1.0%	$19.45	$14.00 ▼ $27.31	$2.92B	1.12	3.16 million shs	2.13 million shs
ELVN Enliven Therapeutics	$41.52 -1.0%	$50.26	$14.78 ▼ $62.32	$3.04B	0.24	1.42 million shs	2.30 million shs
RCUS Arcus Biosciences	$18.54 -4.2%	$26.12	$16.87 ▼ $31.74	$2.36B	0.94	2.40 million shs	5.93 million shs

The Best Nuclear Energy Stocks to Buy

Nuclear energy is entering a new growth cycle as rising power demand, expanding data centers, and renewed policy support bring the sector back into focus. After strong gains in recent years, the most impactful phase of nuclear investment may still be ahead. This report highlights seven nuclear energy stocks positioned across the value chain—combining near-term revenue with long-term upside as next-generation technologies scale. Click the link below to unlock the full list.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ATXS Astria Therapeutics	0.00%	0.00%	0.00%	0.00%	+3.03%
DYN Dyne Therapeutics	0.00%	+9.61%	-5.39%	-36.09%	-4.46%
ELVN Enliven Therapeutics	0.00%	+11.25%	-8.08%	-21.59%	+102.64%
RCUS Arcus Biosciences	0.00%	-15.96%	-26.09%	-34.73%	+11.02%

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ATXS Astria Therapeutics	$12.58 +0.6%	$12.68	$3.69 ▼ $13.29	$718.13M	0.01	1.01 million shs	3.20 million shs
DYN Dyne Therapeutics	$15.62 -1.0%	$19.45	$14.00 ▼ $27.31	$2.92B	1.12	3.16 million shs	2.13 million shs
ELVN Enliven Therapeutics	$41.52 -1.0%	$50.26	$14.78 ▼ $62.32	$3.04B	0.24	1.42 million shs	2.30 million shs
RCUS Arcus Biosciences	$18.54 -4.2%	$26.12	$16.87 ▼ $31.74	$2.36B	0.94	2.40 million shs	5.93 million shs

The Best Nuclear Energy Stocks to Buy

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ATXS Astria Therapeutics	0.00%	0.00%	0.00%	0.00%	+3.03%
DYN Dyne Therapeutics	0.00%	+9.61%	-5.39%	-36.09%	-4.46%
ELVN Enliven Therapeutics	0.00%	+11.25%	-8.08%	-21.59%	+102.64%
RCUS Arcus Biosciences	0.00%	-15.96%	-26.09%	-34.73%	+11.02%

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
ATXS Astria Therapeutics	1.67	Reduce	N/A	N/A
DYN Dyne Therapeutics	2.75	Moderate Buy	$33.07	111.72% Upside
ELVN Enliven Therapeutics	2.67	Moderate Buy	$75.44	81.71% Upside
RCUS Arcus Biosciences	2.69	Moderate Buy	$39.64	113.75% Upside

Current Analyst Ratings Breakdown

Latest ATXS, DYN, ELVN, and RCUS Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
10/21/2026	RCUS Arcus Biosciences	Citigroup Subscribe to MarketBeat All Access to unlock brokerage rankings	Boost Price Target	Buy	$45.00 ➝ $50.00
10/21/2026	RCUS Arcus Biosciences	Truist Financial Subscribe to MarketBeat All Access to unlock brokerage rankings	Boost Price Target	Buy	$40.00 ➝ $41.00
10/21/2026	RCUS Arcus Biosciences	Wedbush Subscribe to MarketBeat All Access to unlock brokerage rankings	Boost Price Target	Outperform	$43.00 ➝ $49.00
10/19/2026	ELVN Enliven Therapeutics	HC Wainwright Subscribe to MarketBeat All Access to unlock brokerage rankings	Boost Price Target	Buy	$65.00 ➝ $73.00
10/16/2026	RCUS Arcus Biosciences	William Blair Subscribe to MarketBeat All Access to unlock brokerage rankings	Initiated Coverage	Outperform
10/15/2026	DYN Dyne Therapeutics	Weiss Ratings Subscribe to MarketBeat All Access to unlock brokerage rankings	Reiterated Rating	Sell (D-)
10/15/2026	ELVN Enliven Therapeutics	Weiss Ratings Subscribe to MarketBeat All Access to unlock brokerage rankings	Reiterated Rating	Sell (D-)
10/15/2026	RCUS Arcus Biosciences	Weiss Ratings Subscribe to MarketBeat All Access to unlock brokerage rankings	Reiterated Rating	Sell (D-)
10/14/2026	RCUS Arcus Biosciences	JPMorgan Chase & Co. Subscribe to MarketBeat All Access to unlock brokerage rankings	Initiated Coverage	Overweight	$41.00
10/13/2026	ELVN Enliven Therapeutics	Zacks Research Subscribe to MarketBeat All Access to unlock brokerage rankings	Downgrade	Hold ➝ Strong Sell
10/8/2026	ELVN Enliven Therapeutics	Guggenheim Subscribe to MarketBeat All Access to unlock brokerage rankings	Reiterated Rating	Buy

(Data available from 10/25/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
ATXS Astria Therapeutics	$706K	1,017.18	N/A	N/A	$3.97 per share	3.17
DYN Dyne Therapeutics	N/A	N/A	N/A	N/A	$6.81 per share	N/A
ELVN Enliven Therapeutics	N/A	N/A	N/A	N/A	$7.74 per share	N/A
RCUS Arcus Biosciences	$247M	9.56	N/A	N/A	$5.84 per share	3.18

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
ATXS Astria Therapeutics	-$94.26M	-$2.14	N/A	N/A	N/A	N/A	-68.81%	-41.12%	N/A
DYN Dyne Therapeutics	-$446.21M	-$3.33	N/A	N/A	N/A	N/A	-64.30%	-50.33%	11/4/2026 (Estimated)
ELVN Enliven Therapeutics	-$103.69M	-$1.67	N/A	N/A	N/A	N/A	-18.55%	-18.09%	11/11/2026 (Estimated)
RCUS Arcus Biosciences	-$353M	-$3.90	N/A	N/A	N/A	-393.16%	-89.54%	-45.61%	10/27/2026 (Estimated)

Latest ATXS, DYN, ELVN, and RCUS Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
11/11/2026	Q3 2026	ELVN Enliven Therapeutics	-$0.4478	N/A	N/A	N/A	N/A	N/A
11/4/2026	Q3 2026	DYN Dyne Therapeutics	-$0.9122	N/A	N/A	N/A	N/A	N/A
11/4/2026	Q3 2026	RCUS Arcus Biosciences	-$0.8912	N/A	N/A	N/A	$7.58 million	N/A
8/5/2026	Q2 2026	ELVN Enliven Therapeutics	-$0.3872	-$0.49	-$0.1028	-$0.49	N/A	N/A
8/5/2026	Q2 2026	RCUS Arcus Biosciences	-$0.8912	-$0.72	+$0.1712	-$0.72	$21.98 million	$41.00 million
7/29/2026	Q2 2026	DYN Dyne Therapeutics	-$0.7488	-$1.08	-$0.3312	-$1.08	N/A	N/A

Compare Dividends

Company	Annual Payout	Dividend Yield	5-Year Annualized Dividend Growth	Payout Ratio	Years of Consecutive Growth
ATXS Astria Therapeutics	N/A	N/A	N/A	N/A	N/A
DYN Dyne Therapeutics	N/A	N/A	N/A	N/A	N/A
ELVN Enliven Therapeutics	N/A	N/A	N/A	N/A	N/A
RCUS Arcus Biosciences	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
ATXS Astria Therapeutics	N/A	10.78	10.78
DYN Dyne Therapeutics	0.28	12.02	12.02
ELVN Enliven Therapeutics	N/A	64.07	64.07
RCUS Arcus Biosciences	0.22	3.82	3.82

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
ATXS Astria Therapeutics	98.98%
DYN Dyne Therapeutics	96.68%
ELVN Enliven Therapeutics	95.08%
RCUS Arcus Biosciences	92.89%

Insider Ownership

Company	Insider Ownership
ATXS Astria Therapeutics	4.50%
DYN Dyne Therapeutics	9.46%
ELVN Enliven Therapeutics	3.00%
RCUS Arcus Biosciences	7.60%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
ATXS Astria Therapeutics	30	57.09 million	54.52 million	Optionable
DYN Dyne Therapeutics	258	186.75 million	169.08 million	Optionable
ELVN Enliven Therapeutics	67	73.27 million	71.07 million	Optionable
RCUS Arcus Biosciences	601	127.33 million	117.66 million	Optionable

ATXS, DYN, ELVN, and RCUS Headlines

Recent News About These Companies

Arcus Biosciences (RCUS) Stock Looks Stretched As Casdatifan Trial Data Impresses

October 24 at 7:05 PM | finance.yahoo.com

Arcus Biosciences Finalizes $269.7M Public Offering with 16.4M Shares at $17.50 Each

October 24 at 9:04 AM | kalkinemedia.comK

Arcus Biosciences (NYSE:RCUS) Sees Strong Trading Volume on Analyst Upgrade

October 24 at 1:52 AM | americanbankingnews.com

Arcus Biosciences (NYSE:RCUS) Stock Moved Down to "Sell" by Wall Street Zen

October 24 at 1:19 AM | americanbankingnews.com

Arcus Biosciences (NYSE:RCUS) Stock Moved Down to Sell by Wall Street Zen

October 24 at 1:17 AM | marketbeat.com

Arcus Biosciences, Inc. closes public offering of 16,428,572 shares of common stock for net proceeds of approximately $269.7 million

October 23 at 11:01 PM | msn.com

Arcus Biosciences Completes $269 Million Common Stock Offering

October 23 at 4:30 PM | tipranks.com

Truist Financial Forecasts Strong Price Appreciation for Arcus Biosciences (NYSE:RCUS) Stock

October 23 at 1:48 AM | americanbankingnews.com

Wedbush Forecasts Strong Price Appreciation for Arcus Biosciences (NYSE:RCUS) Stock

October 23 at 1:48 AM | americanbankingnews.com

Arcus Biosciences, Inc. (RCUS) Discusses New Data on Casdatifan for Kidney Cancer Across Multiple Lines of Therapy - Slideshow

October 22 at 9:30 PM | seekingalpha.com

Arcus Biosciences Prices $250 Mln Public Offering At $17.50/Share

October 22 at 11:28 AM | rttnews.com

Arcus Biosciences Announces Commencement of Public Offering of Common Stock - October 21, 2026

October 22 at 11:28 AM | biospace.comB

Arcus Shares Fall After Offering Priced

October 22 at 11:28 AM | marketwatch.com

Arcus Biosciences, Inc. estimates $694.0 million in cash, cash equivalents and marketable securities as of September 30, 2026

October 22 at 11:28 AM | msn.com

Arcus Biosciences Prices $250 Million Common Stock Offering; Shares Down Pre-Bell

October 22 at 11:28 AM | finance.yahoo.com

Arcus Biosciences slides 20% on stock offering, kidney-cancer data

October 22 at 11:28 AM | seekingalpha.com

Arcus Biosciences prices $250M public offering at $17.50 per share

October 22 at 11:28 AM | msn.com

Arcus Biosciences (NYSE:RCUS) Sees Large Volume Increase Following Analyst Upgrade

October 22 at 10:19 AM | marketbeat.com

Arcus Biosciences Announces Pricing of $250 Million Public Offering of Common Stock

October 21, 2026 | businesswire.com

Arcus Biosciences, Inc. Presents New Data from ARC-20 Evaluating Casdatifan Across All Lines of Therapy in Kidney Cancer

October 21, 2026 | marketscreener.comM

Kuehn Law Encourages Investors of Arcus Biosciences, Inc. to Contact Law Firm

October 21, 2026 | prnewswire.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All

ATXS, DYN, ELVN, and RCUS Company Descriptions

Astria Therapeutics NASDAQ:ATXS

Astria Therapeutics, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutics for allergic and immunological diseases in the United States. Its lead product candidate is STAR-0215, a monoclonal antibody inhibitor of plasma kallikrein, which is in Phase 1b/2 clinical trials for the treatment of hereditary angioedema. The company is also developing STAR-0310, a monoclonal antibody OX40 antagonist that is in preclinical development for the treatment of atopic dermatitis, an immune disorder associated with loss of skin barrier function and itching. The company was formerly known as Catabasis Pharmaceuticals, Inc. and changed its name to Astria Therapeutics, Inc. in September 2021. Astria Therapeutics, Inc. was incorporated in 2008 and is headquartered in Boston, Massachusetts.

Dyne Therapeutics NASDAQ:DYN

$15.62 -0.15 (-0.95%)

Closing price 10/23/2026 04:00 PM Eastern

Extended Trading

$15.60 -0.02 (-0.13%)

As of 10/23/2026 07:30 PM Eastern

Dyne Therapeutics, Inc., a clinical-stage muscle disease company, operates as a biotechnology company that focuses on advancing therapeutics for genetically driven muscle diseases in the United States. It is developing a portfolio of muscle disease therapeutics, including programs in myotonic dystrophy type 1; duchenne muscular dystrophy; and facioscapulohumeral dystrophy, as well as rare skeletal muscle, and cardiac and metabolic muscle diseases using its FORCE platform that delivers disease-modifying therapeutics. Dyne Therapeutics, Inc. was incorporated in 2017 and is headquartered in Waltham, Massachusetts.

Enliven Therapeutics NASDAQ:ELVN

$41.52 -0.41 (-0.98%)

Closing price 10/23/2026 04:00 PM Eastern

Extended Trading

$41.86 +0.34 (+0.83%)

As of 10/23/2026 07:30 PM Eastern

Enliven Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of small molecule inhibitors to help patients with cancer. The company's lead product candidates comprise ELVN-001, which is being evaluated in a Phase 1 clinical trial in adults with chronic myeloid leukemia; and ELVN-002, a Phase 1 clinical trial in adults with solid tumors with HER2 alterations. The company is headquartered in Boulder, Colorado.

Arcus Biosciences NYSE:RCUS

$18.54 -0.82 (-4.22%)

Closing price 10/23/2026 03:59 PM Eastern

Extended Trading

$18.57 +0.03 (+0.17%)

As of 10/23/2026 07:30 PM Eastern

Arcus Biosciences, Inc., a clinical-stage biopharmaceutical company, develops and commercializes cancer therapies in the United States. The company's pipeline products include Domvanalimab, an anti-TIGIT antibody, which is in Phase 2 and Phase 3 clinical trial; and AB308, an investigational anti-TIGIT monoclonal antibody, which is in Phase 1b clinical trial to study people with advanced solid and hematologic malignancies. It also develops Etrumadenant, a dual A2a/A2b adenosine receptor antagonist, which is in Phase 2 clinical trial; Quemliclustat, a small-molecule CD73 inhibitor, which is Phase 1b and Phase 2 clinical trial; Zimberelimab, an anti-PD-1 antibody, which is in Phase 2 clinical trial for metastatic cell lung cancer and monotherapy; and AB521, an oral and small-molecule inhibitor of HIF-2a, which is in Phase 1 clinical trial for the treatment of Von Hippel-Lindau disease. In addition, the company's preclinical pipeline products include AB598, a CD39 antibody; and AB801, a small molecule Axl inhibitor. It has a clinical collaboration with AstraZeneca to evaluate domvanalimab in combination with durvalumab in a registrational phase 3 clinical trial in patients with unresectable Stage 3 NSCLC; and BVF Partners L.P. to support the discovery and development of compounds for the treatment of inflammatory diseases. Arcus Biosciences, Inc. was incorporated in 2015 and is headquartered in Hayward, California.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest ATXS, DYN, ELVN, and RCUS Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest ATXS, DYN, ELVN, and RCUS Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

ATXS, DYN, ELVN, and RCUS Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

ATXS, DYN, ELVN, and RCUS Company Descriptions

Astria Therapeutics NASDAQ:ATXS

Dyne Therapeutics NASDAQ:DYN

Enliven Therapeutics NASDAQ:ELVN

Arcus Biosciences NYSE:RCUS

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest ATXS, DYN, ELVN, and RCUS Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest ATXS, DYN, ELVN, and RCUS Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

ATXS, DYN, ELVN, and RCUS Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

ATXS, DYN, ELVN, and RCUS Company Descriptions

Astria Therapeutics NASDAQ:ATXS

Dyne Therapeutics NASDAQ:DYN

Enliven Therapeutics NASDAQ:ELVN

Arcus Biosciences NYSE:RCUS

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools